A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

Lupus Erythematosus, Systemic Clinical Trial

Official title:

A Phase 2A , Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Subjects With Systemic Lupus Erythematosus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00657189
• Other study ID #: MI-CP179
• Status: Completed
• Phase: Phase 2
• First received: April 9, 2008
• Last updated: August 5, 2016
• Start date: July 2008
• Est. completion date: May 2010

Study information

• Verified date: August 2016
• Source: MedImmune LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and tolerability of multiple doses of MEDI-545 in subjects with moderately to severely active Lupus.

Description:

The primary objective of this study is to evaluate the safety and tolerability of multiple SC doses of MEDI-545 in subjects ≥ 18 years of age with moderately to severely active SLE despite standard of care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: May 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female subjects = 18 years at the time of the first dose of study drug;

• Written informed consent and HIPAA authorization (applies to covered entities in the US only) obtained from the subject or subject's legal representative;

• Meet at least 4 of the 11 revised ACR classification criteria for SLE

• Have positive antinuclear antibody test (ANA) at = 1:80 serum dilution documented in the past or at screening;

• Have at least 1 system with a score of A or 2 systems with a score of B on the BILAG index at screening, or have a SELENA-SLEDAI score = 6;

• Treatment for SLE with antimalarials, oral prednisone or another systemic corticosteroid, mycophenolate mofetil, methotrexate, leflunomide, azathioprine, or dapsone;

• Women, unless surgically sterile or at least 2 years post-menopausal, must use an effective method of avoiding pregnancy (including oral, injectable, transdermal, or implanted contraceptives, intrauterine device, diaphragm with spermicide, cervical cap, abstinence, or sterile sexual partner) in addition to the use of condoms (male or female condoms with spermicide) from screening through the end of the study. Cessation of birth control after this point should be discussed with a responsible physician. Men unless surgically sterile, must likewise practice 2 effective methods of birth control (condom with spermicide or abstinence) from Study Day 0 through the end of the study;

• Ability to complete the study period, including the follow-up period through Study Day 168; and

• Willing to forego other forms of experimental treatment during the study.

Exclusion Criteria:

• Have received MEDI-545 within 120 days prior to screening;

• History of allergy or reaction to any component of the study drug formulation;

• Have received the following medications within 28 days before randomization:

• Systemic cyclophosphamide at any dose

• Cyclosporine at any dose

• Thalidomide at any dose

• Hydroxychloroquine > 600 mg/day

• Mycophenolate mofetil > 3 g/day

• Methotrexate > 25 mg/week

• Azathioprine > 3 mg/kg/day

• Have received fluctuating doses of the following within 28 days before randomization:

• Antimalarials

• Mycophenolate mofetil

• Methotrexate

• Leflunomide

• Azathioprine

• Dapsone

• Have received Leflunomide > 20mg/day in the 6 months prior to Study Day 0;

• Have received prednisone > 20 mg/day or in fluctuating doses within 14 days before randomization;

• Have received fluctuating doses of non-steroidal anti-inflammatory drugs within 14 days before randomization;

• Treatment with any investigational drug therapy within 28 days before randomization into the study, B cell-depleting therapies within 12 months before randomization, or biologic therapies within 30 days or 5 half-lives of the biologic agent, whichever is longer, before randomization into the study;

• In the investigator's opinion, evidence of clinically significant active infection, including ongoing, chronic infection, within 28 days before randomization;

• A history of severe viral infection as judged by the investigators, including severe infections of either cytomegalovirus or the herpes family such as disseminated herpes, herpes encephalitis, ophthalmic herpes;

• Herpes zoster infection within 3 months before randomization;

• Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus (HIV)-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening

• Vaccination with live attenuated viruses within 28 days before randomization;

• Pregnancy (women, unless surgically sterile or at least 2 years post-menopausal, must have a negative serum pregnancy test within 28 days before receiving the study drug and a negative urine pregnancy test on days of study drug administration before receiving the study drug);

• Breastfeeding or lactating women;

• History of primary immunodeficiency;

• History of alcohol or drug abuse < 1 year prior to randomization;

• History of cancer (except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy > 1 year prior to randomization);

• History of active tuberculosis (TB) infection or newly positive TB skin test (defined as a reaction = 10 mm in diameter if not on systemic immunosuppressive medication or = 5 mm if on systemic immunosuppressive medication;

• History of latent TB infection without completion of an appropriate course of treatment;

• Elective surgery planned from the time of screening through Study Day 168;

• At screening blood tests (within 28 days before randomization), any of the following:

• AST > 2.5 x upper limit of the normal range (ULN), unless caused by SLE

• ALT > 2.5 x ULN, unless caused by SLE

• Creatinine > 4.0 mg/dL

• Neutrophils < 1,500/mm3

• Platelet count < 50,000/mm3

• History of any disease, evidence of any current disease (other than SLE), any finding upon physical examination, or any laboratory abnormality that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study; or

• Any employee of the research site who is involved with the conduct of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lupus
• Lupus Erythematosus, Systemic

Intervention

Drug:
• MEDI-545
100 mg once; SC Placebo × 12 doses on other weeks
• MEDI-545
100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
• MEDI-545
100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
• MEDI-545
100 mg every week × 13 doses
• Placebo
SC Placebo every week × 13 doses

Locations

Country	Name	City	State
United States	Research Site	Anniston	Alabama
United States	Research Site	Atlanta	Georgia
United States	Research Site	Baltimore	Maryland
United States	Research Site	Brooklyn	New York
United States	Research Site	Charleston	South Carolina
United States	Research Site	Charlotte	North Carolina
United States	Research Site	Cincinnati	Ohio
United States	Research Site	Clearwater	Florida
United States	Research Site	Colorado Springs	Colorado
United States	Research Site	Columbia	South Carolina
United States	Research Site	Decatur	Georgia
United States	Research Site	Farmington	Connecticut
United States	Research Site	Houston	Texas
United States	Research Site	Huntington Beach	California
United States	Research Site	Lansing	Michigan
United States	Research Site	Marrietta	Georgia
United States	Research Site	Ocala	Florida
United States	Research Site	Oklahoma	Oklahoma
United States	Research Site	Seattle	Washington
United States	Research Site	Sugarland	Texas
United States	Research Site	Upland	California
United States	Research Site	West Fayetteville	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
MedImmune LLC

Country where clinical trial is conducted

United States, 

References & Publications (1)

Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalim — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The safety and tolerability of MEDI-545 will be assessed primarily by summarizing treatment emergent AEs and SAEs and by assessing changes in viral cultures.		Immediately following the first administration of study drug through Study Day 168.	Yes
Secondary	A secondary endpoint of this study is to assess certain measures of disease activity including PK, and PD of SC doses of MEDI-545.		At Study Day 98	Yes